Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey-Reference-Cited by-同舟云学术

Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey

Published:2023-06 Issue:6 Volume:11 Page:e917-e923
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Kennedy Stephen B,Macklin Grace R,Mason Ross Gloria,Lopez Cavestany Rocio,Moukom Richelot A,Jones Kathryn A V,Mainou Bernardo A,Massaquoi Moses B F,Kieh Mark W S,Mach Ondrej

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world;Lancet Glob Health,2020

2. Vaccine-derived polioviruses and the endgame strategy for global polio eradication;Kew;Annu Rev Microbiol,2005

3. Vaccine-derived polioviruses;Burns;J Infect Dis,2014

4. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2020–June 2021;Alleman;MMWR Morb Mortal Wkly Rep,2021

5. Statement of the thirty-first polio IHR Emergency Committee [press release March 11, 2022],2022

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel oral poliovirus vaccine type 2 is an important eradication tool, but reaching every last child remains vital;The Lancet Infectious Diseases;2024-04

2. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study;The Lancet Infectious Diseases;2024-04

3. Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study;The Lancet Infectious Diseases;2024-04

4. First Africa-based clinical trial for novel type 2 oral poliovirus vaccine;The Lancet;2024-03

5. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial;The Lancet;2024-03